News
GYRE
7.49
-4.10%
-0.32
Weekly Report: what happened at GYRE last week (0630-0704)?
Weekly Report · 5d ago
Weekly Report: what happened at GYRE last week (0623-0627)?
Weekly Report · 06/30 10:00
Gyre Therapeutics: Unique Business Model, Unique Challenges
Seeking Alpha · 06/30 09:37
Stifel Nicolaus Initiates a Buy Rating on Gyre Therapeutics (GYRE)
TipRanks · 06/24 23:25
Weekly Report: what happened at GYRE last week (0616-0620)?
Weekly Report · 06/23 09:57
Innovative Strategy and Strong Pipeline Position Gyre Therapeutics for Market Success
TipRanks · 06/18 10:17
Weekly Report: what happened at GYRE last week (0609-0613)?
Weekly Report · 06/16 10:00
GYRE THERAPEUTICS INC - F230 NDA SUBMISSION TO NMPA PLANNED FOR Q3 2025
Reuters · 06/10 11:00
GYRE THERAPEUTICS ANNOUNCES FIRST DOSING IN PHASE 1 TRIAL OF F230 FOR PULMONARY ARTERIAL HYPERTENSION IN CHINA
Reuters · 06/10 11:00
Weekly Report: what happened at GYRE last week (0602-0606)?
Weekly Report · 06/09 10:00
Gyre Therapeutics Holds 2025 Annual Stockholders Meeting
TipRanks · 06/06 10:34
Weekly Report: what happened at GYRE last week (0526-0530)?
Weekly Report · 06/02 10:03
Press Release: Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Dow Jones · 05/29 20:01
MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday
Benzinga · 05/27 14:56
Gyre Therapeutics Up Nearly 24%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk
Dow Jones · 05/27 14:46
Weekly Report: what happened at GYRE last week (0519-0523)?
Weekly Report · 05/26 10:03
Gyre Therapeutics Announces Stock Offering Agreement
TipRanks · 05/23 21:40
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 05/23 17:06
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
TipRanks · 05/23 16:05
BUZZ-U.S. STOCKS ON THE MOVE-Oklo, Uranium stocks, Workday 
Reuters · 05/23 15:58
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.